|
|
| (One intermediate revision by the same user not shown) |
| Line 7: |
Line 7: |
| <ref>Rosen M D, Venkatesan H, Peltier H M, Bembenek S D, Kanelakis K C, Zhao L X, Leonard B E, Hocutt F M, Wu X, Palomino H L, Brondtetter T I, Haugh P V, Cagnon L, Yan W, Liotta L A, Young A, Mirzadegan T, Shankley N P, Barrett T D, Rabinowitz M H. Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues. ACS Medicinal Chemical Letters. 2010 Oct 5.</ref> For more detalis see [[Molecular Playground/Prolyl Hydroxylase Domain (PHD) Enzyme]]. | | <ref>Rosen M D, Venkatesan H, Peltier H M, Bembenek S D, Kanelakis K C, Zhao L X, Leonard B E, Hocutt F M, Wu X, Palomino H L, Brondtetter T I, Haugh P V, Cagnon L, Yan W, Liotta L A, Young A, Mirzadegan T, Shankley N P, Barrett T D, Rabinowitz M H. Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues. ACS Medicinal Chemical Letters. 2010 Oct 5.</ref> For more detalis see [[Molecular Playground/Prolyl Hydroxylase Domain (PHD) Enzyme]]. |
|
| |
|
| </StructureSection>
| |
| == 3D Structures of prolyl hydroxylase domain == | | == 3D Structures of prolyl hydroxylase domain == |
| Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
| |
| {{#tree:id=OrganizedByTopic|openlevels=0|
| |
|
| |
| *Prolyl hydroxylase domain containing Mn
| |
|
| |
| **[[5l9r]] - hPHD2 catalytic domain residues 181-426 (mutant) + Mn + 2OG - human<br />
| |
| **[[3hqr]], [[5l9b]] - hPHD2 catalytic domain (mutant) + Mn + HIF 1 α C terminal + 2OG<br />
| |
| **[[5l9v]], [[5la9]], [[5las]] - hPHD2 catalytic domain (mutant) + Mn + HIF NODD domain + 2OG<br />
| |
| **[[4bqw]], [[4bqx]], [[4bqy]] - hPHD2 catalytic domain + Mn + quinolin derivative<br />
| |
| **[[6st3]] - hPHD2 catalytic domain + Mn + pyrimidin derivative<br />
| |
| **[[6yvt]] - hPHD2 catalytic domain + Mn + pyridin derivative<br />
| |
| **[[6qgv]], [[5a3u]], [[6st3]], [[6yvt]], [[6zbn]], [[6zbo]] - hPHD2 catalytic domain + Mn + inhibitor<br />
| |
| **[[5ox6]], [[6ox5]] - hPHD2 catalytic domain + Mn + drug<br />
| |
| **[[5lat]], [[5lb6]], [[5lbb]], [[5lbc]], [[5lbe]], [[5lbf]], [[4uwd]] - hPHD2 catalytic domain (mutant) + Mn + quinolin derivative<br />
| |
| **[[6yvx]], [[6yvz]] - hPHD2 catalytic domain + Mn + peptide<br />
| |
| **[[6yw3]] - hPHD2 catalytic domain + Mn + peptide + oxalylglycine<br />
| |
| **[[6yw1]], [[6yw2]], [[6yw4]] - hPHD2 catalytic domain (mutant) + Mn + peptide + oxalylglycine<br />
| |
|
| |
|
| *Prolyl hydroxylase domain containing other metal ions
| | [[Polyl hydroxylase domain 3D structures]] |
|
| |
|
| **[[2y33]] – hPHD2 catalytic domain residues + Zn + quinolin derivative – human<br />
| |
| **[[3ouh]], [[3oui]], [[5v18]], [[6nmq]], [[6yvw]], [[6yw0]] - hPHD2 catalytic domain + Fe + inhibitor<br />
| |
| **[[4kbz]] - hPHD2 catalytic domain (mutant) + Fe + inhibitor<br />
| |
| **[[4jzr]] - hPHD2 catalytic domain + Ni + inhibitor<br />
| |
| **[[3ouj]] - hPHD2 catalytic domain + Fe + 2OG<br />
| |
| **[[3hqu]] - hPHD2 catalytic domain + Fe + HIF 1 α C terminal + quinolin derivative<br />
| |
| **[[2hbt]], [[2hbu]], [[2g19]], [[2g1m]], [[2y34]], [[4bqi]] - hPHD2 catalytic domain + Fe + quinolin derivative<br />
| |
| **[[5v18]] - hPHD2 catalytic domain + Fe + pyridin derivative<br />
| |
| **[[5v1b]] - hPHD1 catalytic domain + Fe + inhibitor<br />
| |
| **[[6nmq]] - hPHD2 catalytic domain + Fe + inhibitor<br />
| |
| }}
| |
| ==References== | | ==References== |
| <references/> | | <references/> |
| | </StructureSection> |
| [[Category:Topic Page]] | | [[Category:Topic Page]] |
| <br /> | | <br /> |
| Created with the participation of [[User:Andrew Winslow|Andrew Winslow]]. | | Created with the participation of [[User:Andrew Winslow|Andrew Winslow]]. |